Gamida Cell Ltd. Announces That The First Patient Has Received A Stem Cell Transplant With Omisirge
Portfolio Pulse from Benzinga Newsdesk
Gamida Cell Ltd. (NASDAQ:GMDA) announced that the first patient has received a stem cell transplant with Omisirge, the only allogeneic stem cell therapy approved by the FDA. The company has exceeded its 2023 launch goals, with 15 transplant centers onboarded across the US and confirmed coverage with payers that cover 90% of commercial lives. Gamida Cell is actively engaged with more than 90% of the top 70 transplant centers, which conduct approximately 80% of transplants. The company plans to expand its team from four to eight account managers by the start of 2024.
September 27, 2023 | 8:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gamida Cell Ltd. has successfully administered the first stem cell transplant with Omisirge, exceeding its 2023 launch goals. This could potentially boost the company's stock in the short term.
The successful administration of the first stem cell transplant with Omisirge and exceeding its 2023 launch goals indicates a positive trajectory for Gamida Cell Ltd. This could potentially attract more investors, leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100